Clinical Attribute

VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026

3 weeks ago talkbio0Tagged 2026, AI-driven, Attitude, Funding, Investments, IPO, M&A activity, MassBio, rates, venture capital, Vital capacity, Window (physical object)

venture capital; VC funding; 2025 H2; 2026 outlook; biotech; MassBio; IPO window; M&A activity; interest rates; AI-driven investment

VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026

3 weeks ago talkbio0Tagged 2026, AI-driven, Attitude, Funding, Investments, IPO, M&A activity, MassBio, rates, venture capital, Vital capacity, Window (physical object)

venture capital; VC funding; 2025 H2; 2026 outlook; biotech; MassBio; IPO window; M&A activity; interest rates; AI-driven investment

VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026

3 weeks ago talkbio0Tagged 2026, AI-driven, Attitude, Funding, Investments, IPO, M&A activity, MassBio, rates, venture capital, Vital capacity, Window (physical object)

venture capital; VC funding; 2025 H2; 2026 outlook; biotech; MassBio; IPO window; M&A activity; interest rates; AI-driven investment

VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026

3 weeks ago talkbio0Tagged 2026, AI-driven, Attitude, Funding, Investments, IPO, M&A activity, MassBio, rates, venture capital, Vital capacity, Window (physical object)

venture capital; VC funding; 2025 H2; 2026 outlook; biotech; MassBio; IPO window; M&A activity; interest rates; AI-driven investment

Zaka VC Invests in DeepSeq.AI to Transform AI-Based Protein Drug Discovery

3 weeks ago talkbio0Tagged AI-based drug discovery, DARPA-funded initiative * *, datasets, DeepSeq, hyperscaled data, Illumina Ventures, Investments, LLM-based technology, prepulse inhibition activity, protein drug discovery, Vital capacity, Zaka

Zaka VC; DeepSeq.AI; protein drug discovery; AI-based drug discovery; hyperscaled data; LLM-based technology; biotech investment; DARPA-funded initiative; Illumina Ventures; PPI datasets

Ultragenyx and Mereo BioPharma Stocks Crash After Late-Stage Setrusumab Trials Fail in Osteogenesis Imperfecta

4 weeks ago talkbio0Tagged Bone Density, Clinical trial failure, Mereo BioPharma, Osteogenesis Imperfecta, setrusumab, Stock Crash, Ultragenyx

Ultragenyx; Mereo BioPharma; setrusumab; osteogenesis imperfecta; clinical trial failure; stock crash; bone mineral density

AC Immune Reports Promising Phase 2 Interim Data for Parkinson’s Immunotherapy ACI-7104.056

2 months ago talkbio0Tagged ACI-7104.056, Actinium, alpha-Synuclein, Biological Markers, Immune, Parkinson 's disease, Phase 2 trial, Stabilization

AC Immune; ACI-7104.056; Parkinson’s disease; Phase 2 trial; alpha-synuclein; biomarker stabilization

ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk

2 months ago talkbio0Tagged ARIA risk, Binding action, Biological Markers, clinical outcomes, Dental Plaque, oligomer selectivity, Phase 1b Trial, PMN310, PRECISE-AD trial, ProMIS Neurosciences, Toxic Oligomers, vascular deposit binding

ProMIS Neurosciences; PMN310; toxic oligomers; ARIA risk; PRECISE-AD trial; peer-reviewed publication; oligomer selectivity; plaque binding; vascular deposit binding; phase 1b trial; biomarkers; clinical outcomes

Ventus Therapeutics Doses First Patient in Phase 2 Trial of VENT-03, an Oral cGAS Inhibitor, in Lupus

2 months ago talkbio0Tagged Autoimmune Diseases, Biological Markers, cardiometabolic, cGAS inhibitor, Clinical Trials, Immunology, inflammaging, interferon pathway, Lupus Erythematosus, Cutaneous, Lupus Vulgaris, oral small molecule, Phase 2 trial, VENT-03, Ventus Therapeutics

Ventus Therapeutics; VENT-03; cGAS inhibitor; Phase 2 trial; lupus; cutaneous lupus erythematosus; autoimmune disease; interferon pathway; biomarkers; oral small molecule; clinical trial; immunology; cardiometabolic; inflammaging

Health tech investors are getting creative with exits in 2025

2 months ago talkbio0Tagged 2025, AI healthtech IPOs, Exit, healthtech, Investments, M&A consolidation, Private Equity, provider operations, roll-ups, secondary markets, trends qualifier, Vital capacity

healthtech exits 2025; creative exit strategies; M&A consolidation; secondary markets; private equity roll-ups; AI healthtech IPOs; provider operations investment; VC healthtech trends